Sivakumar Naveen, Krishnamoorthy Ashwin, Ryali Harshita, Arasaradnam Ramesh P
Institute of Precision Diagnostics & Translational Medicine, University Hospitals Coventry & Warwickshire, Coventry CV2 2DX, UK.
Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
Biomedicines. 2025 Mar 14;13(3):716. doi: 10.3390/biomedicines13030716.
Inflammatory bowel disease (IBD) is a debilitating condition in which surgery is often seen as a last resort. However, this is associated with morbidity and, in some cases, mortality. There are emerging therapies that seek to better modulate the immune response of hosts with IBD. : The main aim of this study is to focus on novel therapies and techniques studied in the last year that are non-surgical treatments of IBD. : We looked at all the research between March 2024 and February 2025 detailing treatment in IBD and focused on the gut microbiome and gene therapy. : Novel therapies are gaining traction in safety and popularity. The results from some animal studies show promise and, with FDA approval, some probiotic therapies show optimistic research potential for future human trials. : The research into the diagnostics and novel therapies available on the horizon for humans is very promising. Animal studies have shown potentially transferrable and safe therapies that can target specific sites of inflammation. Modulating the inflammatory response is a powerful therapy with what is shown to be a reasonably safe profile to build further research on.
炎症性肠病（IBD）是一种使人衰弱的疾病，手术通常被视为最后的手段。然而，这与发病率相关，在某些情况下还与死亡率相关。目前正在出现一些疗法，旨在更好地调节IBD宿主的免疫反应。本研究的主要目的是关注去年研究的新型疗法和技术，这些都是IBD的非手术治疗方法。我们查阅了2024年3月至2025年2月期间所有详细介绍IBD治疗的研究，并重点关注肠道微生物群和基因治疗。新型疗法在安全性和受欢迎程度方面越来越受到关注。一些动物研究的结果显示出希望，并且在获得美国食品药品监督管理局（FDA）批准后，一些益生菌疗法显示出对未来人体试验具有乐观的研究潜力。对人类可用的诊断方法和新型疗法的研究非常有前景。动物研究已经显示出可以靶向特定炎症部位的潜在可转移且安全的疗法。调节炎症反应是一种强有力的疗法，其安全性表现合理，可为进一步的研究奠定基础。
